Empowering Precision Oncology with CRISPR: From Mutation to Target Discovery and Mechanistic Insights

Tumor genomes are characterized by extensive genetic heterogeneity, harboring thousands of somatic variants across coding and non-coding regions. However, only a limited subset of these alterations act as true driver mutations that confer selective growth advantages, promote malignant transformation, or mediate therapeutic resistance. The majority remain passenger variants with minimal functional impact. Therefore, distinguishing driver from passenger mutations is essential for understanding tumor biology and for prioritizing clinically actionable targets.

A major challenge in cancer research lies in the functional interpretation of variants identified through high-throughput sequencing, particularly variants of uncertain significance (VUS). Experimental systems that enable precise, locus-specific manipulation of these variants are critical for establishing causal relationships between genotype and phenotype.

CRISPR-based precision genome editing technologies, including Prime Editing, provide a powerful framework for this purpose. By enabling accurate single-nucleotide substitutions, insertions, or corrections at endogenous loci, these approaches preserve native genomic context, epigenetic regulation, and transcriptional control. This allows for the generation of isogenic cellular models, in which the functional consequences of individual mutations can be systematically evaluated without confounding background variation.

Such models support mechanistic investigations into how specific mutations alter signaling pathway activity, cellular fitness, and drug response, and are particularly valuable for dissecting allele-specific effects within the same gene.

Explore Point Mutation Models View Prime Editing Solutions

Tumor cells, following the acquisition of oncogenic alterations, often become highly dependent on a subset of genes for survival and proliferation—a phenomenon known as tumor dependency or oncogene addiction. These dependencies reflect functional rewiring of cellular networks and represent critical vulnerabilities that can be therapeutically exploited.

Large-scale CRISPR screening efforts, including the Broad Institute and Wellcome Sanger Institute Cancer Dependency Map initiatives, have systematically profiled gene essentiality across hundreds of cancer cell lines. These studies reveal that each cancer cell line depends on approximately ~500 genes, with the vast majority of these dependencies being highly context-specific, often restricted to particular tissue types or genetic backgrounds.

Importantly, dependencies driven by gain-of-function events—such as oncogenic mutations or aberrant overexpression—are significantly more prevalent than classical synthetic lethal interactions. This highlights a key strategy in cancer research: modeling clinically relevant mutations to uncover downstream dependency networks, thereby enabling mechanism-based target discovery.

1. 1. Targeting “Undruggable” Oncogenes via Dependency Networks
2. Certain oncogenic drivers (e.g., KRAS, MYC, mutant TP53) remain challenging to target directly. However, tumor cells often rely on downstream pathways or compensatory mechanisms activated by these drivers. Systematic dependency mapping enables identification of genes that are essential in tumor cells but dispensable in normal cells, providing actionable intervention points for indirect targeting strategies.

Effective cancer drug targets typically share three key features: essentiality for tumor survival, selective dependency in cancer cells, and pharmacological tractability. With the advancement of CRISPR-based functional genomics, these properties can now be systematically evaluated through integrated dependency profiling and gene perturbation studies.

Mutation → Dependency → Target → Validation